Hyperion Therapeutics, Inc. announced that the first patient has been enrolled in its phase II clinical trial of investigational acerbate HPN-100 (glycerol phenylbutyrate). The multi-center study consists of an open label safety constituent followed by a randomized, double-blind, placebo-controlled study that will enroll approximately 140 work with episodic hepatic encephalopathy in the US and Eastern Europe. The primary efficacy measure will be the proportion of profession who exhibit a hepatic encephalopathy episode during the four-month rehabilitation period...

More: - Brought to my attention by